News and Updates

AstraZeneca has terminated a Phase 3 lung cancer trial for a bispecific antibody after failing to meet efficacy goals. Read the latest clinical update here.

EyePoint Pharmaceuticals shares fell sharply following disappointing clinical data for its lead wet AMD drug, EYP-1901. Learn what this means for investors.

A new clinical trial confirms cold-stored platelets are a safe, viable way to extend shelf life and solve critical blood supply shortages for patients.

Discover how the fourth-generation retinoid trifarotene is changing acne treatment with its highly selective RAR-gamma targeting for face and body.

OncoC4 has dosed the first patient in a Phase 1 trial for ONC-783. Explore the potential of this novel therapy in treating advanced solid tumors.

Hidden fatalities in China’s IIT trials spark global alarm. Learn why transparency and bioethical oversight are critical for future clinical trial safety.

Explore the latest 2026 interim results from Kelun-Biotech. Discover key growth in ADC research, clinical pipeline progress, and global expansion strategies.

Clinical trials are underway for a groundbreaking heavy-chain-only antibody, a new class of biologics that could revolutionize targeted medical therapy.

Fate Therapeutics begins Phase II trials for FT819, an iPSC-derived CAR-T therapy, targeting improved outcomes for patients with lupus nephritis.

AstraZeneca halts a key lung cancer trial, determining its bispecific drug cannot outperform Keytruda. Learn about the strategic shift in oncology R&D.